Global FSGS Treatment Market to Reach $44.5 Billion by 2031: Soaring at 8.25% CAGR Driven by Increasing Prevalence, Demand for Effective Therapies, and R&D Advancements - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

The global focal segmental glomerulosclerosis (FSGS) treatment market size was valued at USD 21.8 billion in 2022 and is projected to grow at a CAGR of 8.25% during the forecast period of 2023-2031 to reach a value of USD 44.5 billion by 2031.

The market growth can be attributed to the increasing prevalence of FSGS and the growing demand for effective treatment options.

Introduction to Global Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease that affects the glomeruli, which are the tiny filtering units in the kidneys. FSGS causes scarring in the glomeruli, which can lead to proteinuria (the presence of excess protein in the urine), edema (swelling), and eventually, kidney failure. FSGS can occur as a primary disease or as a result of another condition, such as obesity, diabetes, or HIV.

There is currently no cure for FSGS, and treatment options are limited. The standard of care includes medications to control blood pressure and reduce proteinuria, as well as immunosuppressive therapies to slow the progression of the disease. In some cases, dialysis or kidney transplantation may be necessary.

Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Analysis

The global FSGS treatment market is expected to experience significant growth during the forecast period, driven by factors such as the increasing prevalence of FSGS, the growing demand for effective treatment options, and advancements in research and development.

The prevalence of FSGS is increasing globally, with a higher incidence observed in certain populations, such as African Americans and Hispanics. The growing prevalence of FSGS is driving the demand for effective treatment options, as patients seek to manage their symptoms and slow the progression of the disease. Advancements in research and development are also contributing to the growth of the FSGS treatment market. There is a significant unmet need for effective treatments for FSGS, and pharmaceutical companies are investing in the development of novel therapies to address this need. In addition, the increasing focus on precision medicine is expected to drive the development of personalized treatment options for FSGS in the future.

Market Segmentations

by Disease Type

• Primary Focal Segmental Glomerulosclerosis
• Secondary Focal Segmental Glomerulosclerosis

by Treatment Type

• Kidney Function Testing
• Kidney Imaging
• Kidney Biopsy

by Treatment Method

• Medication
• Dialysis
• Kidney Transplant

by Treatment Channel

• Public
• Private

Key Players in the Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market

The report provides a detailed analysis of the key players involved in the FSGS treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:

• Beckman Coulter Inc. (Danaher Corporation)
• Complexa Inc
• Variant Pharmaceuticals, Inc
• Travere Therapeutics, Inc
• Sanofi S.A
• Pfizer Inc
• GlaxoSmithKline Plc
• Aurinia Pharmaceuticals Inc
• Medtronic Plc
• B. Braun Melsungen AG
• Bristol-Myers Squibb Co
• Reata Pharmaceuticals Inc
• Kyowa Hakko Kirin Co., Ltd
• Astellas Pharma Inc.

For more information about this report visit https://www.researchandmarkets.com/r/4v66x4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.